TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. is the post-merger operating company formed through the business combination with MedTech Acquisition Corp (Nasdaq: MTAC), a healthcare-focused special purpose acquisition company that completed its IPO in 2021. MTAC targeted the medical device and life sciences sector, ultimately merging with TriSalus, a company focused on oncology drug delivery technology. The entity filed an 8-K with the SEC on June 16, 2025, continuing its post-combination public reporting obligations. As a de-SPAC'd company, TriSalus remains an active Nasdaq-listed issuer in the life sciences space. For full filing history, deal timelines, and SPAC metrics on MTAC and thousands of other transactions, sign up for complete data access at SpacDesk.